Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

S Read, V Malmström, F Powrie, S Read, V Malmström, F Powrie

Abstract

It is now clear that functionally specialized regulatory T (Treg) cells exist as part of the normal immune repertoire, preventing the development of pathogenic responses to both self- and intestinal antigens. Here, we report that the Treg cells that control intestinal inflammation express the same phenotype (CD25(+)CD45RB(low)CD4(+)) as those that control autoimmunity. Previous studies have failed to identify how CD25(+) Treg cells function in vivo. Our studies reveal that the immune-suppressive function of these cells in vivo is dependent on signaling via the negative regulator of T cell activation cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), as well as secretion of the immune-suppressive cytokine transforming growth factor beta. Strikingly, constitutive expression of CTLA-4 among CD4(+) cells was restricted primarily to Treg cells, suggesting that CTLA-4 expression by these cells is involved in their immune-suppressive function. These findings raise the possibility that Treg cell function contributes to the immune suppression characteristic of CTLA-4 signaling. Identification of costimulatory molecules involved in the function of Treg cells may facilitate further characterization of these cells and development of new therapeutic strategies for the treatment of inflammatory diseases.

Figures

Figure 1
Figure 1
CD4+ regulatory T cells that control intestinal inflammation are CD25+CD45RBlow. (a) Representative photomicrographs show severe colitis in mice that received CD45RBhighCD4+ cells alone. (b) Inhibition of colitis in mice given CD45RBhigh plus 2 × 105 unfractionated CD45RBlowCD4+ cells. (c) Regulatory T cell function is enriched within the CD25+CD45RBlow subset, as 105 CD25+CD45RBlow cells inhibited colitis when transferred with CD45RBhighCD4+ cells, whereas (d) mice restored with a mixture of 105 CD25−CD45RBlow and CD45RBhighCD4+ cells developed severe colitis. Severe colitis in mice restored with (e) CD45RBhigh and 2 × 105 CD45RBlowCD4+ cells or (f) CD45RBhigh and 105 CD25+CD45RBlowCD4+ cells and treated with anti-CTLA-4 mAb. Mice receiving CD45RBhigh and CD45RBlowCD4+ cells or CD45RBhigh and CD25+CD45RBlowCD4+ cells and treated with control hamster IgG were similar to those shown in b. Original magnification: ×80.
Figure 2
Figure 2
Anti–CTLA-4 treatment abrogates the function of regulatory T cells. (a) SCID mice were reconstituted with CD45RBhighCD4+ cells alone (□) or in combination with 2 × 105 CD45RBlowCD4+ cells and treated with anti–CTLA-4 mAb (•) or purified hamster IgG (○). Asterisk indicates one of five mice killed on D32. Data represent the mean ± SEM for five mice per group. For CD45RBhigh versus CD45RBhigh plus CD45RBlow cells plus control IgG, P < 0.05. For CD45RBhigh versus CD45RBhigh plus CD45RBlow cells plus anti–CTLA-4, results were not significant (Student's t test). (b) SCID mice were reconstituted with CD45RBhigh cells alone and received anti–CTLA-4 mAb (▪) or control hamster IgG (□). Data represent the mean ± SEM for six mice per group. (c) SCID mice received CD45RBhighCD4+ cells (□), 2 × 105 CD45RBlow cells (⋄), both CD45RBhighCD4+ cells and 2 × 105 CD45RBlow cells (○), or CD45RBhighCD4+ cells in combination with 105 CD25+CD45RBlow CD4+ cells (▵). Mice also received either anti–CTLA-4 (filled symbols) or control hamster IgG (open symbols). Data are pooled from three independent experiments. Significant protection was mediated by CD45RBlow cells (P < 0.01) and CD25+ cells (P < 0.01). Adminstration of anti–CTLA-4 mAb abrogated protection mediated by CD45RBlow cells (P < 0.01) and CD25+ cells (P < 0.05).
Figure 2
Figure 2
Anti–CTLA-4 treatment abrogates the function of regulatory T cells. (a) SCID mice were reconstituted with CD45RBhighCD4+ cells alone (□) or in combination with 2 × 105 CD45RBlowCD4+ cells and treated with anti–CTLA-4 mAb (•) or purified hamster IgG (○). Asterisk indicates one of five mice killed on D32. Data represent the mean ± SEM for five mice per group. For CD45RBhigh versus CD45RBhigh plus CD45RBlow cells plus control IgG, P < 0.05. For CD45RBhigh versus CD45RBhigh plus CD45RBlow cells plus anti–CTLA-4, results were not significant (Student's t test). (b) SCID mice were reconstituted with CD45RBhigh cells alone and received anti–CTLA-4 mAb (▪) or control hamster IgG (□). Data represent the mean ± SEM for six mice per group. (c) SCID mice received CD45RBhighCD4+ cells (□), 2 × 105 CD45RBlow cells (⋄), both CD45RBhighCD4+ cells and 2 × 105 CD45RBlow cells (○), or CD45RBhighCD4+ cells in combination with 105 CD25+CD45RBlow CD4+ cells (▵). Mice also received either anti–CTLA-4 (filled symbols) or control hamster IgG (open symbols). Data are pooled from three independent experiments. Significant protection was mediated by CD45RBlow cells (P < 0.01) and CD25+ cells (P < 0.01). Adminstration of anti–CTLA-4 mAb abrogated protection mediated by CD45RBlow cells (P < 0.01) and CD25+ cells (P < 0.05).
Figure 2
Figure 2
Anti–CTLA-4 treatment abrogates the function of regulatory T cells. (a) SCID mice were reconstituted with CD45RBhighCD4+ cells alone (□) or in combination with 2 × 105 CD45RBlowCD4+ cells and treated with anti–CTLA-4 mAb (•) or purified hamster IgG (○). Asterisk indicates one of five mice killed on D32. Data represent the mean ± SEM for five mice per group. For CD45RBhigh versus CD45RBhigh plus CD45RBlow cells plus control IgG, P < 0.05. For CD45RBhigh versus CD45RBhigh plus CD45RBlow cells plus anti–CTLA-4, results were not significant (Student's t test). (b) SCID mice were reconstituted with CD45RBhigh cells alone and received anti–CTLA-4 mAb (▪) or control hamster IgG (□). Data represent the mean ± SEM for six mice per group. (c) SCID mice received CD45RBhighCD4+ cells (□), 2 × 105 CD45RBlow cells (⋄), both CD45RBhighCD4+ cells and 2 × 105 CD45RBlow cells (○), or CD45RBhighCD4+ cells in combination with 105 CD25+CD45RBlow CD4+ cells (▵). Mice also received either anti–CTLA-4 (filled symbols) or control hamster IgG (open symbols). Data are pooled from three independent experiments. Significant protection was mediated by CD45RBlow cells (P < 0.01) and CD25+ cells (P < 0.01). Adminstration of anti–CTLA-4 mAb abrogated protection mediated by CD45RBlow cells (P < 0.01) and CD25+ cells (P < 0.05).
Figure 3
Figure 3
CTLA-4 is expressed constitutively on CD25+CD45RBlow CD4+ cells. (a–c) CTLA-4 staining on permeabilized (a) CD45RBhighCD4+, (b) CD25+CD45RBlowCD4+, and (c) CD25−CD45RBlowCD4+ splenocytes. SSC, side scatter. (d–f) CTLA-4 expression on the progeny of (e) CD25+CD45RBlowCD4+ and (d and f) CD45RBhighCD4+ cells after transfer into immunodeficient mice. C57BL/6 recombination activating gene (RAG)2−/− mice received CD45RBhighCD4+ cells from C57BL/6 mice (CD45.2) (d) alone or (e and f) in combination with 105 CD25+CD45RBlowCD4+ cells from C57BL/6.SJL.CD45 congenic mice (CD45.1). 4 wk after transfer, cells from the mesenteric lymph nodes were stained for CTLA-4 and congenic marker expression. Results are representative of four mice (CD45RBhigh alone) and seven mice (CD45RBhigh plus CD25+) from two independent experiments.
Figure 4
Figure 4
Regulation of colitis by CD25+CD4+ cells is TGF-β dependent. SCID mice received CD45RBhighCD4+ cells alone (□) or in combination with 105 CD25+ cells (▵). Mice also received either anti–TGF-β (filled symbols) or PBS (open symbols). Significant protection mediated by CD25+ cells (P < 0.01) abrogated by treatment with anti–TGF-β mAb (P < 0.02).

References

    1. Tlaskalova H., Kamarytova V., Mandel L., Prokesova L., Kruml J., Lanc A., Miler I. The immune response of germ-free piglets after peroral monocontamination with living Escherichia coli strain 086. I. The fate of antigen, dynamics and site of antibody formation, nature of antibodies and formation of heterohaemagglutinins. Folia Biol. (Praha). 1970;16:177–187.
    1. Powrie F. T cells in inflammatory bowel diseaseprotective and pathogenic roles. Immunity. 1995;3:171–174.
    1. Powrie F., Leach M.W., Mauze S., Caddle L.B., Coffman R.L. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 1993;5:1461–1471.
    1. Morrissey P.J., Charrier K., Braddy S., Liggitt D., Watson J.D. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J. Exp. Med. 1993;178:237–244.
    1. Leach M.W., Bean A.G., Mauze S., Coffman R.L., Powrie F. Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am. J. Pathol. 1996;148:1503–1515.
    1. Powrie F., Leach M.W., Mauze S., Menon S., Caddle L.B., Coffman R.L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1:553–562.
    1. Powrie F., Mauze S., Coffman R.L. CD4+ T-cells in the regulation of inflammatory responses in the intestine. Res. Immunol. 1997;148:576–581.
    1. Aranda R., Sydora B.C., McAllister P.L., Binder S.W., Yang H.Y., Targan S.R., Kronenberg M. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J. Immunol. 1997;158:3464–3473.
    1. Powrie F., Carlino J., Leach M.W., Mauze S., Coffman R.L. A critical role for transforming growth factor β but not interleukin 4 in the suppression of T helper type 1–mediated colitis by CD45RBlow CD4+ T cells. J. Exp. Med. 1996;183:2669–2674.
    1. Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 1999;190:995–1004.
    1. Fowell D., Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J. Exp. Med. 1993;177:627–636.
    1. Saoudi A., Seddon B., Heath V., Fowell D., Mason D. The physiological role of regulatory T cells in the prevention of autoimmunitythe function of the thymus in the generation of the regulatory T cell subset. Immunol. Rev. 1996;149:195–216.
    1. Sakaguchi S., Fukuma K., Kuribayashi K., Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J. Exp. Med. 1985;161:72–87.
    1. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995;155:1151–1164.
    1. Suri-Payer E., Amar A.Z., Thornton A.M., Shevach E.M. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 1998;160:1212–1218.
    1. Asano M., Toda M., Sakaguchi N., Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 1996;184:387–396.
    1. Thornton A.M., Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998;188:287–296.
    1. Takahashi T., Kuniyasu Y., Toda M., Sakaguchi N., Itoh M., Iwata M., Shimizu J., Sakaguchi S. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cellsinduction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 1998;10:1969–1980.
    1. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune systemturning lymphocytes off. Science. 1998;280:243–248.
    1. Lanzavecchia A., Sallusto F. From synapses to immunological memorythe role of sustained T cell stimulation. Curr. Opin. Immunol. 2000;12:92–98.
    1. Shahinian A., Pfeffer K., Lee K.P., Kundig T.M., Kishihara K., Wakeham A., Kawai K., Ohashi P.S., Thompson C.B., Mak T.W. Differential T cell costimulatory requirements in CD28-deficient mice. Science. 1993;261:609–612.
    1. Allison J.P. CD28-B7 interactions in T-cell activation. Curr. Opin. Immunol. 1994;6:414–419.
    1. June C.H., Bluestone J.A., Nadler L.M., Thompson C.B. The B7 and CD28 receptor families. Immunol. Today. 1994;15:321–331.
    1. Walunas T.L., Bakker C.Y., Bluestone J.A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 1996;183:2541–2550.
    1. Krummel M.F., Allison J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 1996;183:2533–2540.
    1. Perez V.L., Van Parijs L., Biuckians A., Zheng X.X., Strom T.B., Abbas A.K. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 1997;6:411–417.
    1. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–1736.
    1. Karandikar N.J., Vanderlugt C.L., Walunas T.L., Miller S.D., Bluestone J.A. CTLA-4a negative regulator of autoimmune disease. J. Exp. Med. 1996;184:783–788.
    1. Perrin P.J., Maldonado J.H., Davis T.A., June C.H., Racke M.K. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 1996;157:1333–1336.
    1. Luhder F., Hoglund P., Allison J.P., Benoist C., Mathis D. Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 1998;187:427–432.
    1. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–988.
    1. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–547.
    1. Chen W., Jin W., Wahl S.M. Engagement of cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) induces transforming growth factor β (TGF-β) production by murine CD4+ T cells. J. Exp. Med. 1998;188:1849–1857.
    1. Coffman R.L. Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development. Immunol. Rev. 1982;69:5–23.
    1. Oosterwegel M.A., Mandelbrot D.A., Boyd S.D., Lorsbach R.B., Jarrett D.Y., Abbas A.K., Sharpe A.H. The role of CTLA-4 in regulating Th2 differentiation. J. Immunol. 1999;163:2634–2639.
    1. Chambers C.A., Allison J.P. Costimulatory regulation of T cell function. Curr. Opin. Cell Biol. 1999;11:203–210.
    1. Linsley P.S., Bradshaw J., Greene J., Peach R., Bennett K.L., Mittler R.S. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity. 1996;4:535–543.
    1. Alegre M.L., Noel P.J., Eisfelder B.J., Chuang E., Clark M.R., Reiner S.L., Thompson C.B. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 1996;157:4762–4770.
    1. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995;182:459–465.
    1. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., Thompson C.B., Bluestone J.A. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405–413.
    1. Metzler B., Burkhart C., Wraith D.C. Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo. Int. Immunol. 1999;11:667–675.
    1. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., Mak T.W., Sakaguchi S. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte–associated antigen 4. J. Exp. Med. 2000;192:303–309.
    1. McCoy K., Camberis M., Gros G.L. Protective immunity to nematode infection is induced by CTLA-4 blockade. J. Exp. Med. 1997;186:183–187.
    1. Bachmann M.F., Kohler G., Ecabert B., Mak T.W., Kopf M. Cutting edgelymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J. Immunol. 1999;163:1128–1131.
    1. Read S., Mauze S., Asseman C., Bean A., Coffman R., Powrie F. CD38+ CD45RBlow CD4+ T cellsa population of T cells with immune regulatory activities in vitro. Eur. J. Immunol. 1998;28:3435–3447.
    1. Seddon B., Mason D. Regulatory T cells in the control of autoimmunitythe essential role of transforming growth factor β and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4+CD45RC− cells and CD4+CD8− thymocytes. J. Exp. Med. 1999;189:279–288.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner